BACKGROUND: The aim of this study was to compare the benefit of beta-blockers (BB) in heart failure (HF) with preserved versus reduced ejection fraction (EF). METHODS AND RESULTS: This was a retrospective study of insured patients who were hospitalized for HF from January 2000 to June 2008. Pharmacy claims were used to estimate BB exposure over 6-month rolling windows. The association between BB exposure and all-cause hospitalization or death was tested with the use of time-updated proportional hazards regression, with adjustment for baseline covariates and other HF medication exposure. The groups were compared by stratification (EF <50% vs ≥50%) and with the use of an EF-group × BB exposure interaction term. A total of 1,835 patients met the inclusion criteria, 741 (40%) with a preserved EF. Median follow-up was 2.1 years. In a fully adjusted multivariable model, BB exposure was associated with a decreased risk of death or hospitalization in both groups (EF <50%: hazard ratio [HR] 0.53 [P < .0001]; EF ≥50%: HR 0.68 [P = .009]). There was no significant difference in this protective association between groups (interaction: P = .32). CONCLUSIONS: BB exposure was associated with a similar protective effect regarding time to death or hospitalization in HF patients regardless of whether EF was preserved or reduced. An adequately powered randomized trial of BB in HF with preserved EF is warranted.
BACKGROUND: The aim of this study was to compare the benefit of beta-blockers (BB) in heart failure (HF) with preserved versus reduced ejection fraction (EF). METHODS AND RESULTS: This was a retrospective study of insured patients who were hospitalized for HF from January 2000 to June 2008. Pharmacy claims were used to estimate BB exposure over 6-month rolling windows. The association between BB exposure and all-cause hospitalization or death was tested with the use of time-updated proportional hazards regression, with adjustment for baseline covariates and other HF medication exposure. The groups were compared by stratification (EF <50% vs ≥50%) and with the use of an EF-group × BB exposure interaction term. A total of 1,835 patients met the inclusion criteria, 741 (40%) with a preserved EF. Median follow-up was 2.1 years. In a fully adjusted multivariable model, BB exposure was associated with a decreased risk of death or hospitalization in both groups (EF <50%: hazard ratio [HR] 0.53 [P < .0001]; EF ≥50%: HR 0.68 [P = .009]). There was no significant difference in this protective association between groups (interaction: P = .32). CONCLUSIONS: BB exposure was associated with a similar protective effect regarding time to death or hospitalization in HF patients regardless of whether EF was preserved or reduced. An adequately powered randomized trial of BB in HF with preserved EF is warranted.
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2009-04-14 Impact factor: 24.094
Authors: L Keoki Williams; Edward L Peterson; Karen Wells; Brian K Ahmedani; Rajesh Kumar; Esteban G Burchard; Vimal K Chowdhry; David Favro; David E Lanfear; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2011-10-21 Impact factor: 10.793
Authors: Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2005-12-15 Impact factor: 24.094
Authors: Barry M Massie; Jeanenne J Nelson; Mary Ann Lukas; Barry Greenberg; Michael B Fowler; Edward M Gilbert; William T Abraham; Sandra R Lottes; Joseph A Franciosa Journal: Am J Cardiol Date: 2007-03-13 Impact factor: 2.778
Authors: Dirk J van Veldhuisen; Alain Cohen-Solal; Michael Böhm; Stefan D Anker; Daphne Babalis; Michael Roughton; Andrew J S Coats; Philip A Poole-Wilson; Marcus D Flather Journal: J Am Coll Cardiol Date: 2009-06-09 Impact factor: 24.094
Authors: Dustin T Smith; Ramin Farzaneh-Far; Sadia Ali; Beeya Na; Mary A Whooley; Nelson B Schiller Journal: Am J Cardiol Date: 2010-01-15 Impact factor: 2.778
Authors: S Morteza Farasat; Dennis T Bolger; Veena Shetty; Elizabeth P Menachery; Gary Gerstenblith; Edward K Kasper; Samer S Najjar Journal: Am J Cardiol Date: 2010-01-15 Impact factor: 2.778
Authors: Christopher J Rush; Ross T Campbell; Pardeep S Jhund; Mark C Petrie; John J V McMurray Journal: Eur Heart J Date: 2018-10-01 Impact factor: 29.983